For instance, integrin β1 contributes to gefitinib resistance via PI3K/Akt signaling in NSCLC, and integrin β3 enhances erlotinib resistance in NSCLC through AXL/YAP pathway [32, 33]. Here, AXL is linked to non-small cell lung carcinoma.